Stocks and InvestingStocks and Investing
Thu, March 10, 2022
Wed, March 9, 2022
Tue, March 8, 2022
Mon, March 7, 2022

David Lebowitz Maintained (ASND) at Buy with Decreased Target to $180 on, Mar 7th, 2022


Published on 2024-10-27 19:59:05 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Decreased Target from $197 to $180 on, Mar 7th, 2022.

David has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022


These are the ratings of the 5 analyists that currently disagree with David


  • Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $170 on, Thursday, March 3rd, 2022
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $117 on, Thursday, March 3rd, 2022
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $188 on, Thursday, March 3rd, 2022
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021